INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 424m ago
HOUSE PTR23m ago
SEC 13F23m ago
ROBINHOOD CHAIN23m ago
Public company

CRLBFCresco Labs Inc.

CIK 0001832928

EDGAR filingsOpen in network
Disclosed transactions0
Buys / sells0 / 0
Max Insider Score—
Connections2with evidence

CRLBF · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2833 · Medicinal Chemicals & Botanical Products · Nov 4, 2026
  • ← Lobbied forevidence
    PUTALASTRATEGIESLDA Q1Y 2026 first quarter · issues not listed · Aug 26, 2026

Lobbying

$160K reported · de-duplicated
2026 Q2 $70K in-house2026 Q1 $90K in-house
  • PUTALASTRATEGIES—2026 Q2 · posted Aug 26, 2026 ·
  • In-house report$90K2026 Q1 · posted Aug 26, 2026 · Banking
  • In-house report$70K2026 Q2 · posted Aug 26, 2026 · Banking
  • PUTALASTRATEGIES—2026 Q1 · posted Aug 26, 2026 ·

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.